Effect of increased CRM₁₉₇ carrier protein dose on meningococcal C bactericidal antibody response.

Clinical and Vaccine Immunology : CVI
Lucia H Lee, Milan S Blake

Abstract

New multivalent CRM(197)-based conjugate vaccines are available for childhood immunization. Clinical studies were reviewed to assess meningococcal group C (MenC) antibody responses following MenC-CRM(197) coadministration with CRM(197)-based pneumococcal or Haemophilus influenzae type b conjugate vaccines. Infants receiving a total CRM(197) carrier protein dose of ∼50 μg and concomitant diphtheria-tetanus-acellular pertussis (DTaP)-containing vaccine tended to have lower MenC geometric mean antibody titers and continued to have low titers after the toddler dose. Nevertheless, at least 95% of children in the reported studies achieved a MenC serum bactericidal antibody (SBA) titer of ≥ 1:8 after the last infant or toddler dose. SBA was measured using an assay with a baby rabbit or human complement source. Additional studies are needed to assess long-term antibody persistence and MenC CRM(197) conjugate vaccine immunogenicity using alternative dosing schedules.

References

Feb 1, 1992·The Journal of Pediatrics·M D DeckerP Palmer
Oct 1, 1991·Infection and Immunity·C C PeetersG T Rijkers
Jan 1, 1986·Annual Review of Microbiology·A A Weiss, E L Hewlett
Sep 1, 1972·Immunochemistry·A M PappenheimerA A Harper
May 6, 1999·The Journal of Infectious Diseases·P RichmondK Cartwright
Feb 15, 2003·BMJ : British Medical Journal·Mary E RamsayElizabeth Miller
Oct 3, 2003·The New England Journal of Medicine·Keith P KlugmanUNKNOWN Vaccine Trialists Group
Apr 14, 2005·JAMA : the Journal of the American Medical Association·Jim P ButteryE Richard Moxon
Mar 29, 2006·The Pediatric Infectious Disease Journal·David GoldblattElizabeth Miller
Dec 23, 2006·Expert Review of Vaccines·Ray Borrow, Elizabeth Miller
Feb 7, 2008·Expert Review of Vaccines·Steven Black
Feb 15, 2008·The Journal of Infectious Diseases·Martin C J MaidenJames M Stuart
Dec 5, 2008·Expert Review of Vaccines·Aruna Chandran, Mathuram Santosham
May 30, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lisa A JacksonUNKNOWN V59P13 Study Group
Jun 23, 2009·Expert Review of Vaccines·Caroline L Trotter, Martin C J Maiden
May 10, 2011·Vaccine·Markus KnufDorothee Kieninger

❮ Previous
Next ❯

Citations

Mar 5, 2016·Human Vaccines & Immunotherapeutics·Michael BrökerPaolo Costantino

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.